Biology & Diagnosis: The 'Atypical' Difference

Atypical Chronic Myeloid Leukemia (aCML) is defined by complex biology within your bone marrow. To understand this condition, it helps to look at it as an overlap syndrome—a disease that acts like two different blood disorders at once ^[1][2].

The Biological Overlap: Proliferation and Dysplasia

In a healthy body, the bone marrow is a regulated system that produces mature, functional blood cells. In an MDS/MPN overlap syndrome like aCML, two major things go wrong simultaneously:

1. Proliferation (The “MPN” Side): The marrow overproduces white blood cells, specifically a type called granulocytes. This leads to a high white blood cell count (leukocytosis) ^[3][1].
2. Dysplasia (The “MDS” Side): Although the marrow is making many cells, they develop abnormally. Doctors call this dysgranulopoiesis—the cells are misshapen and do not function correctly, similar to the defective cells seen in Myelodysplastic Syndromes (MDS) ^[4][3].

Diagnostic Thresholds

Because aCML shares features with several other diseases, doctors use very specific laboratory thresholds, along with clinical evaluation, to confirm the diagnosis. A high WBC count is a diagnostic threshold, not necessarily an immediate medical emergency:

• White Blood Cell (WBC) Count: Must be at least 13,000 per microliter (expressed as ≥13 x 10⁹/L) ^[1][5].
• Immature Myeloid Cells: These are developing blood cells that normally stay in the marrow but have entered the blood. In aCML, they make up 10% or more of your total white blood cells ^[3][1].
• Blasts: These are primitive blood cells. In aCML, blasts must be less than 20% in the blood and marrow. If they reach or exceed 20%, it generally signals that the disease has transformed into Acute Myeloid Leukemia (AML) ^[4][2].
• Monocytes: Monocytes must make up less than 10% of the white blood cells. If they are higher, and other clinical criteria are met, the diagnosis might be a different overlap disease called CMML ^[4][6].
• Cytopenias: The ICC classification requires the presence of at least one cytopenia (like low red blood cells or platelets) to confirm the MDS component ^[3].

Ruling Out the “Look-Alikes”

Diagnosing aCML is a process of integration and exclusion. Your doctor had to prove your condition was not one of these similar-sounding diseases:

• Classic CML: Doctors look for the BCR::ABL1 fusion. If this is present, you have classic CML. In aCML, it is always absent ^[7][8].
• Chronic Neutrophilic Leukemia (CNL): In CNL, the white blood cells look mature, and most patients have a specific mutation called CSF3R. In aCML, the cells show prominent dysplasia ^[4][9].
• CMML: As mentioned above, CMML is defined by persistent monocytosis. aCML is defined by a high number of neutrophils ^[10][6].
• Other Genetic Neoplasms: Doctors must also exclude other specific gene rearrangements, such as PDGFRA/B, FGFR1, and PCM1-JAK2, which define entirely different treatments ^[4].

The Role of Genetics

While no single mutation defines aCML, certain genetic changes act as supportive clues. Scientists use Next-Generation Sequencing (NGS) to look for these markers:

• SETBP1 and ASXL1: These are the most common mutations found in aCML. Finding them supports the diagnosis, but they can be found in other blood cancers too, and they do not currently have approved targeted treatments ^[3][11].
• ETNK1 and CSF3R: These mutations are uncommon but sometimes serve as supportive findings or help differentiate aCML from other neoplasms ^[12][13]. Finding them (or not finding them) does not automatically confirm or rule out the disease.

Understanding these biological details helps your care team evaluate your prognosis and decide whether an intensive treatment approach, like a stem cell transplant, is appropriate for your specific case.